ICUI VS SDGR Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility

Performance

ICUI
10/100

ICUI returned -45.55% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

SDGR
100/100

SDGR returned 38.43% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

ICUI
65/100

5 analysts offer 12-month price targets for ICUI. Together, they have an average target of 190, the most optimistic target put ICUI at 190 within 12-months and the most pessimistic has ICUI at 190.

SDGR

"Analyst Price Targets" not found for SDGR

Technicals

ICUI
25/100

ICUI receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

SDGR
68/100

SDGR receives a 67 of 100 based on 14 indicators. 9 are bullish, 4 are bearish.

Earnings

ICUI
41/100

ICUI has missed earnings 3 times in the last 20 quarters.

SDGR
10/100

SDGR has missed earnings 9 times in the last 20 quarters.

Profit

ICUI
51/100

Out of the last 20 quarters, ICUI has had 13 profitable quarters and has increased their profits year over year on 5 of them.

SDGR
19/100

Out of the last 20 quarters, SDGR has had 3 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

ICUI
48/100

ICUI has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

SDGR
53/100

SDGR has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

All score calculations are broken down here to help you make more informed investing decisions

ICU Medical Inc Summary

Nasdaq / ICUI
Healthcare
Medical - Instruments & Supplies
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

Schrodinger, Inc. Common Stock Summary

Nasdaq / SDGR
Healthcare
Medical - Healthcare Information Services
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.